ImmunityBio, Inc.
IBRX
$2.33
-$0.05-2.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.22% | 3.33% | 74.65% | 10.31% | 2.40% |
| Total Depreciation and Amortization | -11.94% | -15.94% | -9.33% | -2.84% | -5.89% |
| Total Amortization of Deferred Charges | -- | -- | -29.66% | -45.88% | -52.54% |
| Total Other Non-Cash Items | -22.20% | 196.17% | -118.37% | -1,491.37% | -41.96% |
| Change in Net Operating Assets | -203.56% | -466.02% | 57.89% | -43.51% | -40.80% |
| Cash from Operations | 20.53% | 19.70% | 26.14% | -13.00% | -25.79% |
| Capital Expenditure | -49.31% | 11.10% | 73.46% | 50.80% | 91.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 70.33% | 115.28% | 17.06% | 781.24% | -64,984.62% |
| Cash from Investing | 68.65% | 111.59% | 337.26% | 516.05% | -498.44% |
| Total Debt Issued | -- | -- | -100.00% | -51.28% | -- |
| Total Debt Repaid | 80.95% | -- | 100.00% | -15.79% | -10.53% |
| Issuance of Common Stock | 230.08% | -98.44% | 1,051.35% | -60.23% | 284.52% |
| Repurchase of Common Stock | 35.08% | 68.92% | 48.59% | 79.58% | -726.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16.06% | -109.60% | -46.68% | -93.44% | 242.98% |
| Foreign Exchange rate Adjustments | 533.33% | 74.36% | 74.07% | 1,200.00% | 220.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,727.02% | 37.49% | -63.87% | -113.49% | 93.48% |